- Home
- NCPL vs VTAK Comparison
NCPL vs VTAK Comparison
Compare NCPL & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- VTAK
- Stock Information
- Founded
- NCPL 1984
- VTAK 2002
- Country
- NCPL United States
- VTAK United States
- Employees
- NCPL N/A
- VTAK N/A
- Industry
- NCPL Investment Managers
- VTAK Medical/Dental Instruments
- Sector
- NCPL Finance
- VTAK Health Care
- Exchange
- NCPL Nasdaq
- VTAK Nasdaq
- Market Cap
- NCPL 1.2M
- VTAK 1.4M
- IPO Year
- NCPL N/A
- VTAK 2018
- Fundamental
- Price
- NCPL $2.01
- VTAK $0.36
- Analyst Decision
- NCPL
- VTAK
- Analyst Count
- NCPL 0
- VTAK 0
- Target Price
- NCPL N/A
- VTAK N/A
- AVG Volume (30 Days)
- NCPL 602.6K
- VTAK 152.4K
- Earning Date
- NCPL 12-16-2024
- VTAK 11-13-2024
- Dividend Yield
- NCPL N/A
- VTAK N/A
- EPS Growth
- NCPL N/A
- VTAK N/A
- EPS
- NCPL N/A
- VTAK N/A
- Revenue
- NCPL $1,702,723.00
- VTAK $399,000.00
- Revenue This Year
- NCPL N/A
- VTAK $637.10
- Revenue Next Year
- NCPL $101.16
- VTAK $177.13
- P/E Ratio
- NCPL N/A
- VTAK N/A
- Revenue Growth
- NCPL N/A
- VTAK 27.07
- 52 Week Low
- NCPL $1.41
- VTAK $0.31
- 52 Week High
- NCPL $22.82
- VTAK $4.10
- Technical
- Relative Strength Index (RSI)
- NCPL 53.43
- VTAK 42.64
- Support Level
- NCPL $1.65
- VTAK $0.34
- Resistance Level
- NCPL $2.10
- VTAK $0.37
- Average True Range (ATR)
- NCPL 0.22
- VTAK 0.04
- MACD
- NCPL -0.03
- VTAK 0.00
- Stochastic Oscillator
- NCPL 40.44
- VTAK 49.90
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.